Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226005 · ClinicalTrials.gov registry record · Phase 2
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Pancreatic Cancer Research Team.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT00226005 is a Phase 2 study that has completed, run by Pancreatic Cancer Research Team. The registered enrollment target is 67 participants.
The verdict
NCT00226005, a Phase 2 study, has completed, sponsored by Pancreatic Cancer Research Team.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer. In order for tumors to grow and spread to other parts of the body, they need to have a growing blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. In adults, blood vessel cells normally divide very rapidly. It is thought that PTK787/ZK222584 may interfere with the growth of new blood vessels. A drug that interferes with the growth of new blood vessels might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Since normal blood vessel cells divide very rarely, it might be possible to stop tumor growth without harming normal tissues.
Interventions
- DRUG PTK787/ZK222584
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226005
The ClinicalTrials.gov registry entry for NCT00226005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pancreatic Cancer Research Team, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTK787/ZK222584 is the first listed.
NCT00226005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00226005 about?
NCT00226005 is a clinical study titled "PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma". The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer. In order for tumors to grow and spread to other parts of the body, they need to have a growing blood supply. Tumor cells have been sh...
What is the current status of trial NCT00226005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2005-12. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00226005?
The interventions under investigation include: PTK787/ZK222584 (DRUG).
Who is sponsoring clinical trial NCT00226005?
This trial is sponsored by Pancreatic Cancer Research Team, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.